Exclusive iVeena speaker interview released for 3rd Ophthalmic Drugs Conference

SMi Group18 - 20 November 2019, London, UK.
Senior expert from iVeena is set to present at SMi's 3rd Annual Ophthalmic Drugs 3 Day Conference. Europe's leading Ophthalmic Drugs conference will explore new discoveries in the treatment of ocular rare disease, innovations in gene therapy, the challenges in drug delivery through a complex barrier, patient comfort and regulatory compliance which make up such core components within the Ophthalmic Drug sphere.

In the run up to the conference, SMi Group caught up with Mike Burr, Vice President of Product Developmentat iVeena, to discuss his upcoming presentation and his thoughts on the current challenges and opportunities in Ophthalmic Drug development.

A snapshot of Mike Burr's interview

Q. The ophthalmic novel drug delivery market has matured greatly over recent years, what are the key significant developments you have noticed over the past year?
A. "For decades now there has been research in both academia and industry into longer term (beyond one day) sustained delivery technologies for direct ocular applications with minimal translation into commercial products. Regulatory approvals by the FDA in the last year in the post-cataract space for treatments intended to replace daily anti-inflammatory eye drops is very exciting. There is also a robust pipeline of sustained delivery glaucoma therapies which could provide chronic IOP lowering capabilities in the near term."

Q. What do you personally see as the greatest challenge to overcome in ophthalmic drug delivery at the moment?
A. "Now that we are seeing the commercialisation of small molecule sustained release products, with hopefully more to come in the near term, the next frontier is in biologics. Large molecule stability for controlled release applications is a tough one."

The full speaker interview and more content including the latest brochure and past attendees can be found in the DOWNLOADS section on the website at www.ophthalmicdrugs.com

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Johnson & Johnson announces collaboration to e…

Johnson & Johnson (the Company) (NYSE: JNJ) announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to...

Researchers urge clinical trial of blood pressure …

Researchers in the Ludwig Center at the Johns Hopkins Kimmel Cancer Center report they have identified a drug treatment that could - if given early enough - potentially r...

Official COVID-19 deaths underestimate the full im…

According to a study by Charité - Universitätsmedizin Berlin, the northern Italian city of Nembro recorded more deaths during March 2020 than between January and December...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Local climate unlikely to drive the early COVID-19…

Local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic, according to a Princeton University study published May 18 in the journal ...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

AstraZeneca advances response to global COVID-19 c…

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations...

Antibody neutralizes SARS and COVID-19 coronavirus…

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the c...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...